Glaxo (GSK) bets big on a new drug for clogged arteries (darapladib), launching a costly...
Glaxo (GSK) bets big on a new drug for clogged arteries (darapladib), launching a costly three-year trial. It hopes patients will experience fewer heart attacks and strokes. The lengthy trial means the drug will not reach the market until well after Pfizer's (PFE) blockbuster Lipitor goes generic.
From other sites
at CNBC.com (Thu, 1:44AM)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (May 6, 2015)
Video at CNBC.com (Jan 23, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs